Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial.
Copland M, Slade D, McIlroy G, Horne G, Byrne JL, Rothwell K, Brock K, De Lavallade H, Craddock C, Clark RE, Smith ML, Fletcher R, Bishop R, Milojkovic D, Yap C. Copland M, et al. Among authors: mcilroy g. Lancet Haematol. 2022 Feb;9(2):e121-e132. doi: 10.1016/S2352-3026(21)00370-7. Epub 2021 Dec 11. Lancet Haematol. 2022. PMID: 34906334 Clinical Trial.
Very early lineage-specific chimerism after reduced intensity stem cell transplantation is highly predictive of clinical outcome for patients with myeloid disease.
Kinsella FAM, Inman CF, Gudger A, Chan YT, Murray DJ, Zuo J, McIlroy G, Nagra S, Nunnick J, Holder K, Wall K, Griffiths M, Craddock C, Nikolousis E, Moss P, Malladi R. Kinsella FAM, et al. Among authors: mcilroy g. Leuk Res. 2019 Aug;83:106173. doi: 10.1016/j.leukres.2019.106173. Epub 2019 Jun 18. Leuk Res. 2019. PMID: 31276965
Azacitidine for the treatment of steroid-refractory chronic graft-versus-host disease: the results of the phase II AZTEC clinical trial.
Malladi R, Ahmed I, McIlroy G, Dignan FL, Protheroe R, Jackson A, Moss P, Nunnick J, Siddique S, Bishop R, Elhaneid M, Hodgkinson A, Craddock C. Malladi R, et al. Among authors: mcilroy g. Bone Marrow Transplant. 2021 Dec;56(12):2948-2955. doi: 10.1038/s41409-021-01439-y. Epub 2021 Aug 26. Bone Marrow Transplant. 2021. PMID: 34446853 Clinical Trial.
A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial.
Fox CP, Ali AS, McIlroy G, Thust S, Martinez-Calle N, Jackson AE, Hopkins LM, Thomas CM, Kassam S, Wright J, Chaganti S, Smith J, Chau I, Culligan D, Linton KM, Collins GP, Ferreri AJM, Lewis D, Davies AJ, Johnson R, Auer DP, Cwynarski K. Fox CP, et al. Among authors: mcilroy g. Blood Adv. 2021 Oct 26;5(20):4073-4082. doi: 10.1182/bloodadvances.2021004779. Blood Adv. 2021. PMID: 34464973 Free PMC article. Clinical Trial.
Ibrutinib as part of risk-stratified treatment for post-transplant lymphoproliferative disorder: The phase 2 TIDaL trial.
Chaganti S, Maycock S, McIlroy G, Jackson AE, Bishop R, Johnson S, Kanfer E, Kassam S, Cwynarski K, Wrench DJ, Arumainathan A, Fox CP, Johnson RJ, McKay P, Paneesha S, Rowntree C, Balotis C, Collins GP, Davies AJ, Wright J, Burns S Dr, Laurence ADJ, Wheatley K, Menne T. Chaganti S, et al. Among authors: mcilroy g. Blood. 2024 Apr 21:blood.2024023847. doi: 10.1182/blood.2024023847. Online ahead of print. Blood. 2024. PMID: 38643491
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia.
Parry H, McIlroy G, Bruton R, Ali M, Stephens C, Damery S, Otter A, McSkeane T, Rolfe H, Faustini S, Wall N, Hillmen P, Pratt G, Paneesha S, Zuo J, Richter A, Moss P. Parry H, et al. Among authors: mcilroy g. Blood Cancer J. 2021 Jul 30;11(7):136. doi: 10.1038/s41408-021-00528-x. Blood Cancer J. 2021. PMID: 34330895 Free PMC article. Clinical Trial.
Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial.
McIlroy G, Lax S, Gaskell C, Jackson A, Rhodes M, Seale T, Fox S, Hopkins L, Okosun J, Barrington SF, Ringshausen I, Ramsay AG, Calaminici M, Linton K, Bishton M. McIlroy G, et al. BMC Cancer. 2024 Mar 25;24(1):370. doi: 10.1186/s12885-024-12112-0. BMC Cancer. 2024. PMID: 38528445 Free PMC article.
59 results